Relay Therapeutics, Inc.
RLAY
Classifica tra le azioni
#4224
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Prezzo delle azioni
$17.16
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$3.76B
Variazione (1 giorno)
5.41%
Variazione (1 anno)
140.34%
Paese
US
Scambia Relay Therapeutics, Inc. (RLAY)
Categoria
Healthcare
Utile per Relay Therapeutics, Inc. (RLAY)
Utile nel Jun 2026 TTM: $-286.04M
Secondo gli ultimi rapporti finanziari di Relay Therapeutics, Inc., gli utili attuali della società sono $-286.04M. Nel 2023, la società ha registrato un utile di $-341.97M, una diminuzione rispetto a agli utili del 2022, che erano di $-290.51M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Relay Therapeutics, Inc. dal 2018 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $-286.04M | -15.30% |
| 2024 | $-337.71M | -1.25% |
| 2023 | $-341.97M | 17.72% |
| 2022 | $-290.51M | -20.16% |
| 2021 | $-363.87M | 594.25% |
| 2020 | $-52.41M | -30.40% |
| 2019 | $-75.31M | 54.36% |
| 2018 | $-48.79M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | -1,944.13% |
US
|
|
| $-3.09B | 979.23% |
US
|
|
| $-4.02B | 1,304.08% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -781.96% |
NL
|
